CN1950364B - 制备天冬氨酸缩醛胱冬酶抑制剂的方法和中间体 - Google Patents
制备天冬氨酸缩醛胱冬酶抑制剂的方法和中间体 Download PDFInfo
- Publication number
- CN1950364B CN1950364B CN2005800144933A CN200580014493A CN1950364B CN 1950364 B CN1950364 B CN 1950364B CN 2005800144933 A CN2005800144933 A CN 2005800144933A CN 200580014493 A CN200580014493 A CN 200580014493A CN 1950364 B CN1950364 B CN 1950364B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- optionally substituted
- represented
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 CC(C)(C)[C@@](C(N(CCC1)[C@@]1C(N[C@@](C1)[C@@](*)*C1=O)=O)=O)NC(OCc1ccccc1)=O Chemical compound CC(C)(C)[C@@](C(N(CCC1)[C@@]1C(N[C@@](C1)[C@@](*)*C1=O)=O)=O)NC(OCc1ccccc1)=O 0.000 description 10
- CRJZBKNZAGFSKJ-UHFFFAOYSA-N CC(C)C1C=C=CC1 Chemical compound CC(C)C1C=C=CC1 CRJZBKNZAGFSKJ-UHFFFAOYSA-N 0.000 description 1
- IJMRUNLMPISGOO-UHFFFAOYSA-N CC(C=C(C)C=C1)N1O Chemical compound CC(C=C(C)C=C1)N1O IJMRUNLMPISGOO-UHFFFAOYSA-N 0.000 description 1
- YIDAFWHCXFSAST-UHFFFAOYSA-N CC(CC(Cl)=C1NC(C)=O)C=C1Cl Chemical compound CC(CC(Cl)=C1NC(C)=O)C=C1Cl YIDAFWHCXFSAST-UHFFFAOYSA-N 0.000 description 1
- ALMHSXDYCFOZQD-UHFFFAOYSA-N CC(Nc1cccc(C)c1)=O Chemical compound CC(Nc1cccc(C)c1)=O ALMHSXDYCFOZQD-UHFFFAOYSA-N 0.000 description 1
- IKLJUPAVTMQKCD-UHFFFAOYSA-N CC1C=C2N=CNC2=CC1 Chemical compound CC1C=C2N=CNC2=CC1 IKLJUPAVTMQKCD-UHFFFAOYSA-N 0.000 description 1
- CIIILUMBZOGKDF-UHFFFAOYSA-N CC1OC=NC1 Chemical compound CC1OC=NC1 CIIILUMBZOGKDF-UHFFFAOYSA-N 0.000 description 1
- IQQNLNOMZISILX-UHFFFAOYSA-N CC1SC=NC1 Chemical compound CC1SC=NC1 IQQNLNOMZISILX-UHFFFAOYSA-N 0.000 description 1
- ASANYKSLSJDAJL-UHFFFAOYSA-N CCOC(C(C1)NC(C(CCC2)N2C(C(C(C)(C)C)NC(OCc2ccccc2)=O)=O)=O)OC1=O Chemical compound CCOC(C(C1)NC(C(CCC2)N2C(C(C(C)(C)C)NC(OCc2ccccc2)=O)=O)=O)OC1=O ASANYKSLSJDAJL-UHFFFAOYSA-N 0.000 description 1
- JGLLCGABBJVUBG-GKSGUAPZSA-N CCO[C@@H]([C@H](C1)NC([C@H](CCC2)N2C([C@H](C(C)(C)C)N)=O)=O)OC1=O Chemical compound CCO[C@@H]([C@H](C1)NC([C@H](CCC2)N2C([C@H](C(C)(C)C)N)=O)=O)OC1=O JGLLCGABBJVUBG-GKSGUAPZSA-N 0.000 description 1
- ASANYKSLSJDAJL-DSXMGRQXSA-N CCO[C@@H]([C@H](C1)NC([C@H](CCC2)N2C([C@H](C(C)(C)C)NC(OCc2ccccc2)=O)=O)=O)OC1=O Chemical compound CCO[C@@H]([C@H](C1)NC([C@H](CCC2)N2C([C@H](C(C)(C)C)NC(OCc2ccccc2)=O)=O)=O)OC1=O ASANYKSLSJDAJL-DSXMGRQXSA-N 0.000 description 1
- SJDDOCKBXFJEJB-MOKWFATOSA-N CCO[C@@H]([C@H](C1)NC([C@H](CCC2)N2C([C@H](C(C)(C)C)NC(c(cc2)cc(Cl)c2N)=O)=O)=O)OC1=O Chemical compound CCO[C@@H]([C@H](C1)NC([C@H](CCC2)N2C([C@H](C(C)(C)C)NC(c(cc2)cc(Cl)c2N)=O)=O)=O)OC1=O SJDDOCKBXFJEJB-MOKWFATOSA-N 0.000 description 1
- CZIGSERRHGUICO-UHFFFAOYSA-N CNC(C1)C(O)OC1=O Chemical compound CNC(C1)C(O)OC1=O CZIGSERRHGUICO-UHFFFAOYSA-N 0.000 description 1
- JXPLDXFZARSBIO-UHFFFAOYSA-N Cc(c(Cl)n1)ccc1OC Chemical compound Cc(c(Cl)n1)ccc1OC JXPLDXFZARSBIO-UHFFFAOYSA-N 0.000 description 1
- KBJTUEYTPBMKAM-UHFFFAOYSA-N Cc(c(OC)c1)cc(Cl)c1N Chemical compound Cc(c(OC)c1)cc(Cl)c1N KBJTUEYTPBMKAM-UHFFFAOYSA-N 0.000 description 1
- BDEUBOJWIKLFSM-UHFFFAOYSA-N Cc(c(OC)n1)ccc1OC Chemical compound Cc(c(OC)n1)ccc1OC BDEUBOJWIKLFSM-UHFFFAOYSA-N 0.000 description 1
- AUJPGGARDMBNMW-UHFFFAOYSA-N Cc(cc1)ccc1C(N1CCOCC1)=O Chemical compound Cc(cc1)ccc1C(N1CCOCC1)=O AUJPGGARDMBNMW-UHFFFAOYSA-N 0.000 description 1
- BKXZNKKZLXRTMG-UHFFFAOYSA-N Cc(cc1)ccc1OCCN1CCOCC1 Chemical compound Cc(cc1)ccc1OCCN1CCOCC1 BKXZNKKZLXRTMG-UHFFFAOYSA-N 0.000 description 1
- IVKILQAPNDCUNJ-UHFFFAOYSA-N Cc1ccc2nc[s]c2c1 Chemical compound Cc1ccc2nc[s]c2c1 IVKILQAPNDCUNJ-UHFFFAOYSA-N 0.000 description 1
- INHYNOZJAVXMJL-UHFFFAOYSA-N Cc1cccc2c1OCO2 Chemical compound Cc1cccc2c1OCO2 INHYNOZJAVXMJL-UHFFFAOYSA-N 0.000 description 1
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N Cc1cnccn1 Chemical compound Cc1cnccn1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 description 1
- AKKFOPCPQBHDOO-AWEZNQCLSA-N O=C([C@H](CCC1)N1C(OCc1ccccc1)=O)NC(CO1)=CC1=O Chemical compound O=C([C@H](CCC1)N1C(OCc1ccccc1)=O)NC(CO1)=CC1=O AKKFOPCPQBHDOO-AWEZNQCLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55248004P | 2004-03-12 | 2004-03-12 | |
| US60/552,480 | 2004-03-12 | ||
| PCT/US2005/008251 WO2005090334A2 (en) | 2004-03-12 | 2005-03-11 | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013103410022A Division CN103467459A (zh) | 2004-03-12 | 2005-03-11 | 制备化合物的方法 |
| CN2011100999799A Division CN102225936B (zh) | 2004-03-12 | 2005-03-11 | 制备化合物的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1950364A CN1950364A (zh) | 2007-04-18 |
| CN1950364B true CN1950364B (zh) | 2011-06-08 |
Family
ID=34962478
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800144933A Expired - Lifetime CN1950364B (zh) | 2004-03-12 | 2005-03-11 | 制备天冬氨酸缩醛胱冬酶抑制剂的方法和中间体 |
| CN2013103410022A Pending CN103467459A (zh) | 2004-03-12 | 2005-03-11 | 制备化合物的方法 |
| CN2011100999799A Expired - Lifetime CN102225936B (zh) | 2004-03-12 | 2005-03-11 | 制备化合物的方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013103410022A Pending CN103467459A (zh) | 2004-03-12 | 2005-03-11 | 制备化合物的方法 |
| CN2011100999799A Expired - Lifetime CN102225936B (zh) | 2004-03-12 | 2005-03-11 | 制备化合物的方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US7381827B2 (https=) |
| EP (3) | EP2399916B1 (https=) |
| JP (2) | JP4898658B2 (https=) |
| KR (2) | KR101135765B1 (https=) |
| CN (3) | CN1950364B (https=) |
| AR (1) | AR048008A1 (https=) |
| AU (1) | AU2005223767B2 (https=) |
| BR (1) | BRPI0508609B8 (https=) |
| CA (3) | CA2843066C (https=) |
| DK (3) | DK1725548T3 (https=) |
| ES (3) | ES2532967T3 (https=) |
| HU (1) | HUE024556T2 (https=) |
| IL (3) | IL178003A (https=) |
| PL (4) | PL381358A1 (https=) |
| PT (3) | PT2399915E (https=) |
| RU (2) | RU2433127C2 (https=) |
| SG (2) | SG150547A1 (https=) |
| SI (3) | SI1725548T1 (https=) |
| TW (3) | TW201200508A (https=) |
| WO (1) | WO2005090334A2 (https=) |
| ZA (1) | ZA200607605B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP1019A (en) | 1996-10-18 | 2001-10-16 | Vertex Pharma | Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease. |
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| UY28500A1 (es) | 2003-09-05 | 2005-04-29 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. |
| EP1718639A2 (en) * | 2004-02-27 | 2006-11-08 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| MXPA06013256A (es) * | 2004-05-15 | 2007-02-08 | Vertex Pharma | Tratamiento de crisis convulsivas utilizando inhibidores ice. |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| AU2007217355B2 (en) | 2006-02-27 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same |
| WO2007109080A2 (en) | 2006-03-16 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
| CA2669917A1 (en) * | 2006-11-17 | 2008-05-22 | Dawn M. George | Aminopyrrolidines as chemokine receptor antagonists |
| HRP20120330T1 (hr) * | 2007-02-27 | 2012-05-31 | Vertex Pharmaceuticals Incorporated | Sukristali i farmaceutski pripravci koji ih sadrže |
| WO2008106058A2 (en) | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| NZ583699A (en) | 2007-08-30 | 2012-04-27 | Vertex Pharma | Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same |
| WO2010017408A1 (en) | 2008-08-06 | 2010-02-11 | The Buck Institute For Age Research | Caspase inhibitors and uses thereof |
| US9113848B2 (en) * | 2010-02-03 | 2015-08-25 | Covidien Lp | Surgical retrieval apparatus |
| JP5769655B2 (ja) * | 2012-03-30 | 2015-08-26 | ユニ・チャーム株式会社 | 吸収性物品 |
| CN103193572B (zh) * | 2013-04-07 | 2015-06-17 | 山东大学 | 一种拉唑类化合物单一对映体的分离方法 |
| ES2950100T3 (es) | 2016-12-23 | 2023-10-05 | Casp Aid Inc | Inhibición de la caspasa-1 y usos de esta para la prevención y el tratamiento de afecciones neurológicas |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| GB9123326D0 (en) | 1991-11-04 | 1991-12-18 | Sandoz Ltd | Improvements in or relating to organic compounds |
| BE1008343A3 (nl) | 1994-05-06 | 1996-04-02 | Dsm Nv | Bidentaat fosfineligand |
| US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| AU704318B2 (en) * | 1995-11-09 | 1999-04-22 | Pq Nederland B.V. | Compacted sodium silicate |
| US5843904A (en) | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
| US6200969B1 (en) | 1996-09-12 | 2001-03-13 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
| KR20000036056A (ko) | 1996-09-12 | 2000-06-26 | 아이디유엔 파마슈티칼즈, 인코포레이티드 | 인터루킨-1β 전환 효소 및 관련 프로테아제의 억제제로서의 Ｃ-말단 변형된 (Ｎ-치환된)-2-인돌릴 디펩티드 |
| EP0929311B8 (en) | 1996-09-12 | 2006-02-01 | Idun Pharmaceuticals, Inc. | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS |
| NZ330451A (https=) | 1996-09-12 | 2000-01-28 | Idun Pharmaceuticals Inc | |
| US5968927A (en) | 1996-09-20 | 1999-10-19 | Idun Pharmaceuticals, Inc. | Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes |
| WO1998016502A1 (en) | 1996-10-11 | 1998-04-23 | Warner-Lambert Company | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
| NZ334906A (en) | 1996-10-11 | 2000-09-29 | Basf Ag | A sulphonamido pentanoic acid derivative useful as an interleukin-1-beta converting enzyme inhibitor |
| US5919790A (en) | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
| AP1019A (en) | 1996-10-18 | 2001-10-16 | Vertex Pharma | Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease. |
| US6184244B1 (en) | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| FR2766188B1 (fr) | 1997-07-15 | 2000-02-11 | Hoechst Marion Roussel Inc | Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| ATE388139T1 (de) | 1997-12-18 | 2008-03-15 | Boehringer Ingelheim Pharma | Pyridone als hemmer der sh2-domäne der src- familie |
| JP2002509153A (ja) | 1998-01-20 | 2002-03-26 | ワーナー−ランバート・カンパニー | インターロイキン−１β変換酵素（ＩＣＥ）のインビボ阻害剤としてのＮ−［２−（５−ベンジルオキシカルボニル−アミノ−６−オキソ−２−（４−フルオロフェニル）−１，６−ジヒドロ−１−ピリミジニル）アセトキシル］−Ｌ−アスパラギン酸アルデヒド |
| DK1064298T3 (da) * | 1998-03-19 | 2009-01-19 | Vertex Pharma | Inhibitorer af caspaser |
| US6197750B1 (en) | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6242422B1 (en) | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| CA2367862A1 (en) | 1999-03-16 | 2000-09-21 | Merck Frosst Canada & Co. | Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| JP2002539183A (ja) | 1999-03-16 | 2002-11-19 | サイトビア インコーポレイテッド | 置換２−アミノベンズアミドカスパーゼインヒビターおよびその使用 |
| CN1176941C (zh) | 1999-04-09 | 2004-11-24 | 西托维亚公司 | Caspase抑制剂及其应用 |
| ES2274795T3 (es) | 1999-07-19 | 2007-06-01 | Merck Frosst Canada Ltd. | Pirazinonas, composiciones que contienen tales compuestos. |
| EP1163208B1 (en) | 1999-08-06 | 2004-05-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| CN1235875C (zh) | 1999-08-27 | 2006-01-11 | 西托维亚公司 | 取代的α－羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途 |
| AR026748A1 (es) | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| PE20011267A1 (es) | 2000-03-29 | 2001-12-15 | Vertex Pharma | Carbamato como inhibidores de caspasa |
| AU2001251165A1 (en) | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| CA2402128A1 (en) * | 2000-04-24 | 2001-11-01 | Vertex Pharmaceuticals Incorporated | Process and intermediates for making substituted aspartic acid acetals |
| TWI291462B (en) | 2000-04-25 | 2007-12-21 | Daiichi Sankyo Co Ltd | Hydrate crystal of neuraminic acid compound |
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| TR200200767T1 (tr) | 2000-05-23 | 2002-09-23 | Vertex Pharmaceuticals Incorporated | Kaspaz engelleyiciler ve kullanımları |
| EP1289993B9 (en) | 2000-06-07 | 2008-08-20 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| CN1498224A (zh) | 2000-07-21 | 2004-05-19 | ���鹫˾ | 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽 |
| WO2002022611A2 (en) | 2000-09-13 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
| AU2002232541A1 (en) | 2000-11-21 | 2002-06-03 | Vertex Pharmaceuticals Incorporated | Imidazole and benzimidazole caspase inhibitors and uses thereof |
| GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
| US20030096737A1 (en) | 2001-04-19 | 2003-05-22 | Anita Diu-Hercend | Caspase inhibitors and uses thereof |
| JP4428926B2 (ja) | 2001-05-23 | 2010-03-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | カスパーゼインヒビターおよびそれらの使用 |
| IL159087A0 (en) | 2001-07-11 | 2004-05-12 | Vertex Pharma | Bridged bicyclic compounds and pharmaceutical compositions containing the same |
| AU2002348533A1 (en) | 2001-10-09 | 2003-05-26 | Vertex Pharmaceuticals Incorporated | Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof |
| US7410956B2 (en) | 2002-02-11 | 2008-08-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitor prodrugs |
| US7960398B2 (en) | 2002-04-19 | 2011-06-14 | Vertex Pharmaceuticals Incorporated | Regulation of TNF-alpha |
| US7138395B2 (en) | 2002-06-10 | 2006-11-21 | The Procter & Gamble Company | Interleukin-1β converting enzyme inhibitors |
| US7001899B2 (en) | 2002-06-10 | 2006-02-21 | The Procter & Gamble Company | Interleukin converting enzyme inhibitors |
| US7041696B2 (en) | 2002-06-17 | 2006-05-09 | The Procter & Gamble Company | Interleukin-1β converting enzyme inhibitors |
| PE20040728A1 (es) | 2002-06-28 | 2004-10-23 | Vertex Pharma | Inhibidores de caspasa |
| TW200500343A (en) | 2002-12-20 | 2005-01-01 | Vertex Pharma | Caspase inhibitors and uses thereof |
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| EP1718639A2 (en) * | 2004-02-27 | 2006-11-08 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
-
2005
- 2005-03-11 SG SG200901309-5A patent/SG150547A1/en unknown
- 2005-03-11 PT PT111781266T patent/PT2399915E/pt unknown
- 2005-03-11 DK DK05728092.7T patent/DK1725548T3/en active
- 2005-03-11 PT PT11178128T patent/PT2399916E/pt unknown
- 2005-03-11 PL PL381358A patent/PL381358A1/pl not_active Application Discontinuation
- 2005-03-11 ES ES11178126.6T patent/ES2532967T3/es not_active Expired - Lifetime
- 2005-03-11 ES ES11178128.2T patent/ES2532433T3/es not_active Expired - Lifetime
- 2005-03-11 CA CA2843066A patent/CA2843066C/en not_active Expired - Fee Related
- 2005-03-11 WO PCT/US2005/008251 patent/WO2005090334A2/en not_active Ceased
- 2005-03-11 RU RU2006136032/04A patent/RU2433127C2/ru active
- 2005-03-11 AR ARP050100964A patent/AR048008A1/es not_active Application Discontinuation
- 2005-03-11 SG SG200901306-1A patent/SG150546A1/en unknown
- 2005-03-11 SI SI200531959T patent/SI1725548T1/sl unknown
- 2005-03-11 CA CA2768700A patent/CA2768700C/en not_active Expired - Fee Related
- 2005-03-11 DK DK11178126T patent/DK2399915T3/en active
- 2005-03-11 AU AU2005223767A patent/AU2005223767B2/en not_active Ceased
- 2005-03-11 US US11/078,147 patent/US7381827B2/en active Active
- 2005-03-11 PL PL05728092T patent/PL1725548T3/pl unknown
- 2005-03-11 BR BRPI0508609A patent/BRPI0508609B8/pt not_active IP Right Cessation
- 2005-03-11 DK DK11178128T patent/DK2399916T3/en active
- 2005-03-11 SI SI200531945T patent/SI2399915T1/sl unknown
- 2005-03-11 CN CN2005800144933A patent/CN1950364B/zh not_active Expired - Lifetime
- 2005-03-11 HU HUE05728092A patent/HUE024556T2/hu unknown
- 2005-03-11 KR KR1020067021136A patent/KR101135765B1/ko not_active Expired - Fee Related
- 2005-03-11 CN CN2013103410022A patent/CN103467459A/zh active Pending
- 2005-03-11 CA CA2559303A patent/CA2559303C/en not_active Expired - Fee Related
- 2005-03-11 PT PT57280927T patent/PT1725548E/pt unknown
- 2005-03-11 EP EP11178128.2A patent/EP2399916B1/en not_active Expired - Lifetime
- 2005-03-11 ES ES05728092.7T patent/ES2533991T3/es not_active Expired - Lifetime
- 2005-03-11 KR KR1020117029981A patent/KR20110137409A/ko not_active Ceased
- 2005-03-11 PL PL11178126T patent/PL2399915T3/pl unknown
- 2005-03-11 EP EP11178126.6A patent/EP2399915B1/en not_active Expired - Lifetime
- 2005-03-11 JP JP2007503066A patent/JP4898658B2/ja not_active Expired - Lifetime
- 2005-03-11 EP EP05728092.7A patent/EP1725548B1/en not_active Expired - Lifetime
- 2005-03-11 CN CN2011100999799A patent/CN102225936B/zh not_active Expired - Lifetime
- 2005-03-11 SI SI200531941T patent/SI2399916T1/sl unknown
- 2005-03-11 PL PL11178128T patent/PL2399916T3/pl unknown
- 2005-03-14 TW TW100133524A patent/TW201200508A/zh unknown
- 2005-03-14 TW TW101124668A patent/TWI399356B/zh not_active IP Right Cessation
- 2005-03-14 TW TW094107737A patent/TWI398426B/zh not_active IP Right Cessation
-
2006
- 2006-09-11 IL IL178003A patent/IL178003A/en active IP Right Grant
- 2006-09-11 ZA ZA200607605A patent/ZA200607605B/xx unknown
-
2008
- 2008-03-07 US US12/074,983 patent/US7834200B2/en not_active Expired - Lifetime
-
2010
- 2010-10-12 US US12/902,811 patent/US8293929B2/en not_active Expired - Lifetime
-
2011
- 2011-07-01 RU RU2011127174/04A patent/RU2011127174A/ru not_active Application Discontinuation
- 2011-10-26 JP JP2011235246A patent/JP2012072151A/ja active Pending
-
2012
- 2012-03-05 IL IL218488A patent/IL218488A0/en unknown
- 2012-03-05 IL IL218487A patent/IL218487A/en active IP Right Grant
- 2012-09-20 US US13/623,563 patent/US20130066083A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1950364B (zh) | 制备天冬氨酸缩醛胱冬酶抑制剂的方法和中间体 | |
| HK1192553A (en) | Processes for the preparation of compound | |
| HK1105955B (en) | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors | |
| HK1163672B (en) | Processes for the preparation of compounds | |
| MXPA06010409A (en) | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors | |
| AU2012201242B2 (en) | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1105955 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1105955 Country of ref document: HK |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20110608 |